risankizumab-rzaa 360 MG per 2.4 ML Cartridge

RxCUI: 2604625
RxNorm name: risankizumab-rzaa 360 MG per 2.4 ML Cartridge
Display name: risankizumab-rzaa 360 MG per 2.4 ML Cartridge
Full name: risankizumab-rzaa 360 MG per 2.4 ML Cartridge
Term type: SY
Status: DailyMed mapping
Updated: 2026-06-04 23:39:03

Purple Book Biologic Products#

BLA, Proprietary name, Proper name table
BLA	Proprietary name	Proper name	License type	Status	Latest source
761105	Skyrizi	risankizumab-rzaa	351(a)	Disc	2026-06-01
761262	Skyrizi	risankizumab-rzaa	351(a)	Rx	2026-06-01

RxNav Current And Historical NDCs#

RxNav current and historical NDC rows page 1 of 1 · 0 matching rows.

No records found.

UNII Substances#

UNII substance links page 1 of 1 · 0 matching rows.

No records found.

openFDA label cross-check#

OpenFDA label data provides additional search and identifier links. DailyMed’s Structured Product Label is the canonical label on FDA.report. Matching records are deduplicated before they are shown below.

Matched openFDA labels page 1 of 1 · 1 matching rows.

Brand, Generic, Manufacturer table
Brand	Generic	Manufacturer	SPL set ID	Effective date	Available safety fields	Join
Skyrizi	RISANKIZUMAB-RZAA	AbbVie Inc.	7148c8eb-b39e-e20a-6494-a6df82392858	2026-06-15	Warnings, Adverse reactions	Exact identifier rxcui: 2604625

DailyMed RxNorm Mappings#

Set ID, RxNorm string, TTY table
Set ID	RxNorm string	TTY	SPL version	Label	Effective
7148c8eb-b39e-e20a-6494-a6df82392858	risankizumab-rzaa 360 MG per 2.4 ML Cartridge	SY	173	These highlights do not include all the information needed to use SKYRIZI safely and effectively. See full prescribing information for SKYRIZI. SKYRIZI ® (risankizumab-rzaa) injection, for subcutaneous or intravenous use Initial U.S. Approval: 2019	20260319
7148c8eb-b39e-e20a-6494-a6df82392858	2.4 ML risankizumab-rzaa 150 MG/ML Cartridge	SCD	173	These highlights do not include all the information needed to use SKYRIZI safely and effectively. See full prescribing information for SKYRIZI. SKYRIZI ® (risankizumab-rzaa) injection, for subcutaneous or intravenous use Initial U.S. Approval: 2019	20260319
7148c8eb-b39e-e20a-6494-a6df82392858	risankizumab-rzaa 360 MG in 2.4 ML Cartridge	PSN	173	These highlights do not include all the information needed to use SKYRIZI safely and effectively. See full prescribing information for SKYRIZI. SKYRIZI ® (risankizumab-rzaa) injection, for subcutaneous or intravenous use Initial U.S. Approval: 2019	20260319